

**Table 1. Detection of antiviral drug-resistant viruses in Japan during the 2019/2020 influenza season**

as of November 12, 2019

	A(H1N1)pdm09						A(H3N2)						B				
	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir	Amantadine	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir	Amantadine	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir
<b>Resistant (%)</b>	0	1 <sup>a</sup> (0.9%)	1 <sup>a</sup> (0.9%)	0	0	4 (100%)	0	0	0	0	0	3 (100%)	0	0	0	0	0
<b>Number of viruses tested</b>	40	106	106	14	14	4	6	4	4	4	4	3	0	2	2	2	2
<b>Number of viruses reported</b>	294						22						18				

Baloxavir was examined by focus reduction assay and/or PA sequencing.

NA inhibitors were examined by fluorescence-based NA-Fluor assay, chemiluminescence-based NA-XTD assay, real time RT-PCR allelic discrimination and/or NA sequencing.

Amantadine was examined by M2 sequencing.

<sup>a</sup> Patient with treatment